Analyst Expectations For Hinge Health's Future
Hinge Health, Inc. Class A HNGE | 38.98 | +1.27% |
Throughout the last three months, 9 analysts have evaluated Hinge Health (NYSE:HNGE), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 6 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 4 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Hinge Health, presenting an average target of $64.11, a high estimate of $71.00, and a low estimate of $59.00. A 2.43% drop is evident in the current average compared to the previous average price target of $65.71.
Interpreting Analyst Ratings: A Closer Look
The perception of Hinge Health by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Gene Mannheimer | Freedom Capital Markets | Announces | Buy | $59.00 | - |
| Jessica Tassan | Piper Sandler | Lowers | Overweight | $60.00 | $71.00 |
| Stan Berenshteyn | Wells Fargo | Announces | Overweight | $68.00 | - |
| Scott Schoenhaus | Keybanc | Lowers | Overweight | $70.00 | $72.00 |
| Ryan MacDonald | Needham | Maintains | Buy | $59.00 | $59.00 |
| Saket Kalia | Barclays | Lowers | Overweight | $60.00 | $65.00 |
| Richard Close | Canaccord Genuity | Raises | Buy | $65.00 | $61.00 |
| Saket Kalia | Barclays | Raises | Overweight | $65.00 | $62.00 |
| Jessica Tassan | Piper Sandler | Raises | Overweight | $71.00 | $70.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Hinge Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hinge Health compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Hinge Health's stock. This comparison reveals trends in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Hinge Health's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Hinge Health analyst ratings.
About Hinge Health
Hinge Health Inc is a technology platform for individuals seeking to treat and prevent joint and muscle pain. Through a combination of AI-powered motion tracking technology, the Company's platform helps members address musculoskeletal (MSK) conditions, enables improved member outcomes and supports cost reductions for its clients. The Company's clients are self-insured employers.
Hinge Health's Economic Impact: An Analysis
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3M period, Hinge Health showcased positive performance, achieving a revenue growth rate of 53.27% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Hinge Health's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -1.2%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Hinge Health's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.97%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Hinge Health's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.25%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Hinge Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.04.
What Are Analyst Ratings?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.